Helicobacter pylori is a naturally occurring bacterium that lives in the stomachs of people and currently infects about 50% of the world’s population. The overwhelming majority of individuals infected with H. pylori are asymptomatic and suffer no ill effects from the bacterium.
Ground breaking work by Ondek® founder Professor Barry Marshall led to the co-discovery of the link between the presence of H. pylori in the stomach of people with gastritis and peptic ulcers. For this work, Professor Marshall and Dr Robin Warren were awarded the Nobel Prize in Physiology or Medicine in 2005.
More recently a beneficial role of H. pylori in humans has been discovered. Epidemiological data show a correlation between H. pylori infection and reduced risk of allergy. Over the last 5 years Ondek® has focused its research activities on allergy and has developed a killed form of H. pylori called ImmBALANCE® that is being tested as an immunotherapy to treat allergic disease.
The company has patented ImmBALANCE® and is developing it as a therapeutic product with the aim of reducing or preventing the allergic response in children, adolescents and adults. Our initial focus will be on paediatric allergy (infants and children), including food allergy and eczema.